Comparison of Four Assays That Measure Antibodies to Ebola Virus Glycoprotein

The accurate measurement of Ebola virus (EBOV)-specific antibody responses is crucial to assessing immunity induced by EBOV infection or vaccination. For this purpose, the Filovirus Animal Nonclinical Group (FANG) anti-EBOV glycoprotein (GP <sub>1,2</sub> ) ELISA is considered the "gold-standard". However, it has limitations such as high repeat-rates and variability, and low throughput. Here, we describe two new alternative assays: a Single-Molecule Assay Planar EBOV GP <sub>1,2</sub> ELISA and a multiplexed EBOV GP <sub>1,2</sub> , EBOV nucleoprotein, and EBOV Viral Protein 40 Luminex assay, and compare these with two versions of the FANG ELISA. Samples were selected from participants receiving vaccine or placebo in a randomized, placebo-controlled, double-blinded study of two EBOV vaccines (PREVAIL 1), and a longitudinal cohort study of Ebola virus disease (EVD) survivors and their close contacts (PREVAIL 3). All four assays were concordant in their measurements of anti-EBOV GP <sub>1,2</sub> -specific immunoglobulin G responses, allowing for the determination of conversion equations for antibody measurements across assays. In addition, all four showed a similar ability to distinguish vaccine recipients from placebo recipients and EVD survivors from their close contacts. Compared to the FANG assays, the Quanterix and Luminex assays had lower variability, lower repeat rates, and higher throughput, making them good alternatives for future studies.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-03-20
DOI
https://doi.org/10.64898/2026.03.18.708022
Primary Topic
Viral Infections and Outbreaks Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparison of Four Assays That Measure Antibodies to Ebola Virus Glycoprotein

Scott M. Anthony, Natasha Dubois Cauwelaert, Ian Crozier, Guillaume Thaurignac et al.
bioRxiv (Cold Spring Harbor Laboratory)
Viral Infections and Outbreaks Research
article

Comparison of Four Assays That Measure Antibodies to Ebola Virus Glycoprotein

Scott M. Anthony, Natasha Dubois Cauwelaert, Ian Crozier, Guillaume Thaurignac, Harrison Gichini, Prabha Chandrasekaran, C. S. Reilly, Richard T. Davey, Patrick Mutombo, Olivier Tshiani Mbaya, Céline Roy, Amie Jarra, Christine Schwimmer, Sarah M. Browne, Nicolas Bernaud, Mosoka Fallah, Emmanuel Lokilo, Lisa Hensley, Edouard Lhomme, Mark Kieh, Neraide Biai, Irina Malkjkovic Berry, Stephen B. Kennedy, Dean A. Follmann, H. Clifford Lane, Yves Lévy, Viviane Callier, Ahidjo Ayouba, Martine Peeters, Safaa Ben Farhat, Laura Richert
article en

Abstract

The accurate measurement of Ebola virus (EBOV)-specific antibody responses is crucial to assessing immunity induced by EBOV infection or vaccination. For this purpose, the Filovirus Animal Nonclinical Group (FANG) anti-EBOV glycoprotein (GP <sub>1,2</sub> ) ELISA is considered the "gold-standard". However, it has limitations such as high repeat-rates and variability, and low throughput. Here, we describe two new alternative assays: a Single-Molecule Assay Planar EBOV GP <sub>1,2</sub> ELISA and a multiplexed EBOV GP <sub>1,2</sub> , EBOV nucleoprotein, and EBOV Viral Protein 40 Luminex assay, and compare these with two versions of the FANG ELISA. Samples were selected from participants receiving vaccine or placebo in a randomized, placebo-controlled, double-blinded study of two EBOV vaccines (PREVAIL 1), and a longitudinal cohort study of Ebola virus disease (EVD) survivors and their close contacts (PREVAIL 3). All four assays were concordant in their measurements of anti-EBOV GP <sub>1,2</sub> -specific immunoglobulin G responses, allowing for the determination of conversion equations for antibody measurements across assays. In addition, all four showed a similar ability to distinguish vaccine recipients from placebo recipients and EVD survivors from their close contacts. Compared to the FANG assays, the Quanterix and Luminex assays had lower variability, lower repeat rates, and higher throughput, making them good alternatives for future studies.

bioRxiv (Cold Spring Harbor Laboratory)
National Institutes of Health (US), University of Minnesota (US), Institut national de recherche en sciences et technologies du numérique (FR), University of Liberia (LR), Université de Bordeaux (FR), Inserm (FR), Université Paris-Est Créteil (FR), Service de Santé des Armées (FR), Planned Parenthood Association of Liberia (LR), Bordeaux Population Health (FR), Agence Nationale de Recherches sur le Sida et les Hépatites Virales (FR), Institut de Recherche Vaccinale (FR), Frederick National Laboratory for Cancer Research (US), National Public Health Institute of Liberia (LR), Institut Bergonié (FR), National Institute of Allergy and Infectious Diseases (US), National Institute of Biomedical Research (CD), Institut de Recherche pour le Développement (FR)
Good health and well-being
Openalex Percentile: Top 15%
Viral Infections and Outbreaks Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.